---
document_datetime: 2025-10-15 14:02:28
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/qinlock-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: qinlock-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.9266097
conversion_datetime: 2025-12-23 05:26:22.0787
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## QINLOCK

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0022/G            | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 09/12/2024                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)             |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10962 /202405 | Periodic Safety Update EU Single assessment - ripretinib                                                                                                                                                     | 28/11/2024 | n/a | PRAC Recommendation - maintenance |
| IB/0020             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                       | 17/09/2024 | n/a |                                   |
| IB/0019             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 17/09/2024 | n/a |                                   |
| IB/0021             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                       | 16/09/2024 | n/a |                                   |
| N/0017              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                             | 27/06/2024 |     |                                   |
| PSUSA/10962 /202305 | Periodic Safety Update EU Single assessment - ripretinib                                                                                                                                                     | 30/11/2023 | n/a | PRAC Recommendation - maintenance |
| IA/0016/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of                                                                                                       | 28/11/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                    |            |            |      |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| IB/0014             | B.II.f.z - Stability of FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/09/2023 | n/a        |      |                                   |
| IAIN/0015/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 17/08/2023 | n/a        |      |                                   |
| IB/0012             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                    | 21/06/2023 | 08/02/2024 | SmPC |                                   |
| PSUSA/10962 /202211 | Periodic Safety Update EU Single assessment - ripretinib                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/06/2023 | n/a        |      | PRAC Recommendation - maintenance |
| IB/0011             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/05/2023 | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

|                     | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10962 /202205 | Periodic Safety Update EU Single assessment - ripretinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 15/12/2022 | 24/02/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10962/202205. |
| IB/0009             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 31/01/2023 | n/a        |             |                                                                                                                                            |
| II/0004             | Update of sections 4.2 and 5.2 of the SmPC in order to change posology recommendations in patients with hepatic impairment and update the description of pharmacokinetics based on final results from Study DCC-2618-01-004; a Phase 1 study of the Pharmacokinetics, Safety, and Tolerability of Ripretinib in Subjects With Hepatic Impairment Compared to Healthy Control Subjects. The Package Leaflet is updated accordingly. The RMP version 2.2 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/01/2023 | 08/02/2024 | SmPC and PL | SmPC new text                                                                                                                              |
| IB/0008             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 08/11/2022 | n/a        |             |                                                                                                                                            |
| IA/0007/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/10/2022 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|             | - Minor changes to an approved test - Change in test procedure for AS or material/reagent/intermediate - Minor to an approved test procedure                                                                                                                                                                                                                                                                                                                                               |            |            |                                  | product procedure B.I.b.2.a starting changes   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------|
| IB/0005     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                             | 18/08/2022 | n/a        |                                  |                                                |
|             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                       | 17/05/2022 | n/a        |                                  | IB/0003                                        |
| II/0002     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                              | 10/03/2022 | n/a        |                                  |                                                |
| IAIN/0001/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 13/12/2021 | 02/12/2022 | SmPC, Annex II, Labelling and PL |                                                |